Literature DB >> 14642306

Polyene and cytokine treatment of experimental aspergillosis.

Edward Sionov1, Esther Segal.   

Abstract

The aim of the present study was to assess the efficacy of amphotericin B (AMB), AMB-intralipid admixture (AMB-IL) or nystatin-IL formulation (Ny-IL) in combination with granulocyte colony stimulating factor (G-CSF) in treatment of experimental murine aspergillosis. ICR mice were immunosuppressed by cyclophosphamide and 3 days later inoculated intravenously (i.v.) with Aspergillus fumigatus. Treatment was initiated 2 h later and administered for 5 consecutive days (polyenes, i.v.; G-CSF, intraperitoneally). Combination therapy, particularly G-CSF with AMB or AMB-IL, significantly increased the survival rate (up to 87.3%) and prolonged the mean survival time (MST) (up to 28.8 days) in comparison to untreated controls (0% survival, MST 6.7 days) and to treatment with polyenes alone (up to 51.5% survival, MST 18.4 days). These data indicate that combination therapy could be beneficial for management of disseminated aspergillosis in humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14642306     DOI: 10.1016/S0928-8244(03)00230-X

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  5 in total

1.  Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis.

Authors:  Gerardo Quezada; Nadezhda V Koshkina; Patrick Zweidler-McKay; Zichao Zhou; Dimitrios P Kontoyiannis; Eugenie S Kleinerman
Journal:  Antimicrob Agents Chemother       Date:  2007-11-05       Impact factor: 5.191

2.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

3.  Nystatin-intralipid preparation: characterization and in vitro activity against yeasts and molds.

Authors:  R Semis; I Polacheck; E Segal
Journal:  Mycopathologia       Date:  2010-01-13       Impact factor: 2.574

4.  Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia.

Authors:  Andrew Y Koh; Gregory P Priebe; Christopher Ray; Nico Van Rooijen; Gerald B Pier
Journal:  Infect Immun       Date:  2009-10-05       Impact factor: 3.441

Review 5.  Immunomodulation for the Treatment of Fungal Infections: Opportunities and Challenges.

Authors:  Muluneh Ademe
Journal:  Front Cell Infect Microbiol       Date:  2020-09-15       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.